首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Targeting the Iron-Response Elements of the mRNAs for the Alzheimer’s Amyloid Precursor Protein and Ferritin to Treat Acute Lead and Manganese Neurotoxicity
【2h】

Targeting the Iron-Response Elements of the mRNAs for the Alzheimer’s Amyloid Precursor Protein and Ferritin to Treat Acute Lead and Manganese Neurotoxicity

机译:靶向阿尔茨海默氏症淀粉样前体蛋白和铁蛋白的mRNA的铁反应元件以治疗急性铅和锰神经毒性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The therapeutic value of inhibiting translation of the amyloid precursor protein (APP) offers the possibility to reduce neurotoxic amyloid formation, particularly in cases of familial Alzheimer’s disease (AD) caused by APP gene duplications (Dup–APP) and in aging Down syndrome individuals. APP mRNA translation inhibitors such as the anticholinesterase phenserine, and high throughput screened molecules, selectively inhibited the uniquely folded iron-response element (IRE) sequences in the 5’untranslated region (5’UTR) of APP mRNA and this class of drug continues to be tested in a clinical trial as an anti-amyloid treatment for AD. By contrast, in younger age groups, APP expression is not associated with amyloidosis, instead it acts solely as a neuroprotectant while facilitating cellular ferroportin-dependent iron efflux. We have reported that the environmental metallotoxins Lead (Pb) and manganese (Mn) cause neuronal death by interfering with IRE dependent translation of APP and ferritin. The loss of these iron homeostatic neuroprotectants thereby caused an embargo of iron (Fe) export from neurons as associated with excess unstored intracellular iron and the formation of toxic reactive oxidative species (ROS). We propose that APP 5’UTR directed translation activators can be employed therapeutically to protect neurons exposed to high acute Pb and/or Mn exposure. Certainly, high potency APP translation activators, exemplified by the Food and Drug Administration (FDA) pre-approved M1 muscarinic agonist AF102B and high throughput-screened APP 5’UTR translation activators, are available for drug development to treat acute toxicity caused by Pb/Mn exposure to neurons. We conclude that APP translation activators can be predicted to prevent acute metal toxicity to neurons by a mechanism related to the 5’UTR specific yohimbine which binds and targets the canonical IRE RNA stem loop as an H-ferritin translation activator.
机译:抑制淀粉样蛋白前体蛋白(APP)的翻译的治疗价值为减少神经毒性淀粉样蛋白的形成提供了可能性,尤其是在APP基因重复(Dup–APP)引起的家族性阿尔茨海默病(AD)以及老年唐氏综合症患者中。 APP mRNA的翻译抑制剂,例如抗胆碱酯酶酚和高通量筛选分子,选择性抑制了APP mRNA 5'非翻译区(5'UTR)中独特折叠的铁反应元件(IRE)序列,此类药物继续在临床试验中作为抗淀粉样蛋白疗法进行测试。相比之下,在较年轻的年龄组中,APP表达与淀粉样变性无关,相反,它仅充当神经保护剂,同时促进细胞依赖铁转运蛋白的铁外排。我们已经报道过,环境金属硫蛋白铅(Pb)和锰(Mn)通过干扰IRE依赖的APP和铁蛋白的翻译而引起神经元死亡。这些铁稳态神经保护剂的损失因此导致了神经元铁(Fe)的禁运,这与过量的未储存的细胞内铁和有毒的反应性氧化物质(ROS)的形成有关。我们建议可以将APP 5’UTR定向翻译激活剂用于治疗,以保护暴露于高急性Pb和/或Mn暴露的神经元。当然,由食品药品管理局(FDA)预先批准的M1毒蕈碱激动剂AF102B和高通量筛选的APP 5'UTR翻译激活剂所代表的高效APP转化激活剂可用于药物开发,以治疗由Pb /锰暴露于神经元。我们得出结论,可以通过与5’UTR特定育亨宾有关的机制来预测APP翻译激活剂来预防对神经元的急性金属毒性,该机制以H-铁蛋白翻译激活剂结合并靶向经典的IRE RNA茎环。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号